The REDEFINE clinical trial program has established that: Cagrilintide 2.4 mg + Semaglutide 2.4 mg weekly produces superior weight loss compared to either agent alone The combination achieved 22.7% mean weight reduction at 68 weeks Side effect profiles were manageable with proper dose escalation The amylin + GLP-1 agonist combination demonstrated synergistic effects This validated combination demonstrates that pairing cagrilintide with incretin-based therapies can work effectively
Studies have proven its success
By controlling cravings on a cellular level, these medications help quiet food noise and make it easier to stay consistent with your nutrition plan, accelerating your transformation
It boasts plaudits from Nasdaq, has blue-chip investors like Fidelity and BlackRock, and Erin Brockovich, the iconic crusader for corporate accountability, sits on its board of directors
Because every persons digestion slows down differently on GLP-1s, fasting alone may not guarantee an empty stomach
What is the usual weekly dose of semaglutide for maintenance